AbbVie’s Skyrizi (risankizumab) Receives European Commission’s Approval for Moderate to Severe Plaque Psoriasis

 AbbVie’s Skyrizi (risankizumab) Receives European Commission’s Approval for Moderate to Severe Plaque Psoriasis

AbbVie’s Skyrizi (risankizumab) Receives European Commission’s Approval for Moderate to Severe Plaque Psoriasis

Shots:

  • The EC approval is based on four P-III ultIMMa-1, ultIMMa-2, IMMvent & IMMhance assessing Skyrizi (risankizumab) vs PBO, adalimumab, ustekinumab in 2000+ adult patients with moderate to severe plaque psoriasis
  • The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%, 84% & 75%); Skyrizi vs adalimumab, PASI 90 (72% vs 47%); switched patients vs continued adalimumab, PASI 90 (66% vs 21%); @16wks. & 52wks. met its co-1EPs; Skyrizi vs ustekinumab, (DLQI) score (75% & 71% vs 47% & 44%)
  • Skyrizi (risankizumab) is a humanized immunoglobulin mAb, inhibits IL-23 by binding to its p19 subunit and has received MHLW’s approval for multiple plaque psoriasis conditions in Mar’19 & Health Canada and the US FDA approval for moderate to severe plaque psoriasis in Apr’19

Click here to read full press release/ article | Ref: AbbVie | Image: The Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post